ATL Health

Incorporating PbD into the software development process of EHR systems presents a strategy to protect information starting from the initial stages of development, and throughout the entire lifecycle of the software.

A Beverly Hills surgeon has sued Medtronic, alleging that the medical device giant stole her design for a hernia mesh device. One lawyer pointed out that this is not a typical patent infringement case.

President-Elect Donald Trump nominated celebrity physician Dr. Mehmet Oz to lead CMS. Healthcare leaders have mixed feelings on the news — for instance, one CEO pointed out that Dr. Oz could advance the food-as-medicine movement, and others noted that his appointment may decrease pharmaceutical innovation and access to certain medications.

Experts aren’t sure what the outcome of the DOJ’s recent lawsuit against the proposed UnitedHealth Group/Amedisys merger will be under the incoming Trump administration. The Biden administration has focused more on supporting clinicians, while the previous Trump administration favored corporations. Additionally, one expert noted that this case differs from other antitrust lawsuits because it does not seem to focus on a potential price increase.

The DEA recently announced the third extension of COVID-19 flexibilities for the virtual prescribing of controlled substances. Telehealth advocates applaud this move but remain hopeful for a more permanent solution in the future.

In the 2024 election, seven out of 10 states passed ballot measures protecting abortion rights. But the effects won't be seen immediately, experts say.

He blamed his cat for the offense, and received a hefty sentence.

Jason Hill, Ochsner Health’s innovation officer, said he goes to sleep most nights and wakes up most mornings worried about one thing: the state of generative AI governance in healthcare. To him, providers and other healthcare organizations are in dire need of frameworks to ensure their AI tools are safe and perform well over time.

In a recent interview, Elizabeth Mitchell, president and CEO of the Purchaser Business Group on Health, discussed employers' challenges in accessing medical data, emphasizing the need for transparency and potential strategies to enhance their fiduciary responsibilities.

Most Americans don’t understand how an administration's view on healthcare data sharing interoperability could directly impact them, pointed out Arcadia CEO Michael Meucci. More requirements around data sharing could lead to better care continuity, improved outcomes and lower costs.

After the FDA delayed the approval of MDMA-assisted therapy for PTSD, there's still a way forward for psychedelic medicines, experts said at HLTH.

More than two dozen Black and Latino health tech leaders have endorsed Kamala Harris for president. Another group of over 500 women healthcare leaders has also come out in support of Harris.

A panel of experts at the HLTH conference agreed that states with strict abortion measures are likely to see negative economic impact as medical residents decline to train there and physicians move out.

Experts from BRG recently discussed the two presidential candidates' stances on key healthcare issues, including drug pricing, Medicaid, and AI.

If you thought that Big Pharma and the PBMs were the only bad guys in the saga of unreasonably high prescription drug prices in the United States, you would be wrong. Hear who else is to blame from the CEO of Blue Shield of California.

During a recent conference, Ceci Connolly, CEO of the Alliance of Community Health Plans, shared five things she thinks the healthcare industry should know about the upcoming election.

Months before the FTC sued the three largest pharmacy benefit managers, the CEO of Blue Shield of California battled its PBM - CVS Caremark - to bring a lower cost prostate cancer drug to its members.

Johnson & Johnson stopped short of implementing its proposal to alter the way two drugs are paid for under the 340B drug discount program, but the drugmaker made it clear it still wants changes. In other recent regulatory news, we have drug approvals, clinical holds, and one product withdrawal.

The Hippocratic oath can’t stop with direct patient care; the healthcare industry and its key stakeholders must address persistent public health problems systematically. We have the tools to reduce medication harm by half or more; it is long past time to make this a public health priority.

A more measured approach to noncompete clauses can be fair to physicians and provider organizations, and also serve patients better. Here are four elements for a policy on noncompetes that will work for healthcare.